Login to Your Account



Potential $330M Deal With Forest

Microbia's IBS Drug: Taking The Place Of Risky Zelnorm?

By Randall Osborne


Monday, September 24, 2007
Coming up with drugs that belong on the radar - and prescription pads - of primary-care doctors is "a challenge that biotech is treading carefully on," as Peter Hecht, CEO of Microbia Inc., told BioWorld Financial Watch last week, but Hecht's firm made a major footfall into the zone with its potential $330 million deal with Forest Laboratories Inc. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription